TC
PTGX icon

Truvestments Capital’s Protagonist Therapeutics PTGX Stock Holding History

Truvestments Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Sell
1,156
-5
-0.4% -$522 0.02% 359
2026
Q1 		$122K Hold
1,161
– – 0.02% 353
2025
Q4 		$101K Buy
1,161
+439
+61% +$35.9K 0.02% 338
2025
Q3 		$48K Buy
722
+72
+11% +$4.09K 0.01% 450
2025
Q2 		$35.9K Buy
650
+369
+131% +$17.7K 0.01% 451
2025
Q1 		$13.6K Buy
281
+150
+115% +$6.29K ﹤0.01% 608
2024
Q4 		$5.06K Hold
131
– – ﹤0.01% 699
2024
Q3 		$5.89K Buy
+131
New +$5.29K ﹤0.01% 661
2024
Q2 		– Sell
-131
Closed -$3.79K – 566
2024
Q1 		$3.79K Hold
131
– – ﹤0.01% 570
2023
Q4 		$3K Hold
131
– – ﹤0.01% 647
2023
Q3 		$2.19K Hold
131
– – ﹤0.01% 584
2023
Q2 		$3.62K Hold
131
– – ﹤0.01% 559
2023
Q1 		$3.01K Sell
131
-214
-62% -$3.59K ﹤0.01% 553
2022
Q4 		$3.76K Hold
345
– – ﹤0.01% 596
2022
Q3 		$3K Hold
345
– – ﹤0.01% 521
2022
Q2 		$3K Buy
+345
New +$4.17K ﹤0.01% 537
2022
Q1 		– Sell
-250
Closed -$9K – 448
2021
Q4 		$9K Hold
250
– – ﹤0.01% 411
2021
Q3 		$4K Hold
250
– – ﹤0.01% 480
2021
Q2 		$11K Hold
250
– – 0.01% 383
2021
Q1 		$6K Buy
250
+131
+110% +$3.31K ﹤0.01% 506
2020
Q4 		$2K Buy
+119
New +$2.56K ﹤0.01% 563
2020
Q3 		– Sell
-119
Closed -$2K – 490
2020
Q2 		$2K Buy
+119
New +$1.49K ﹤0.01% 516
2019
Q4 		– Sell
-119
Closed -$1K – 466
2019
Q3 		$1K Hold
119
– – ﹤0.01% 684
2019
Q2 		$1K Hold
119
– – ﹤0.01% 701
2019
Q1 		$1K Buy
+119
New +$1.05K ﹤0.01% 705
2018
Q3 		$3K Buy
+252
New +$2.17K ﹤0.01% 778

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Truvestments Capital's PTGX Position: Q2 2026 in Review

Truvestments Capital reduced its Protagonist Therapeutics (PTGX) stake by 0.43% in Q2 2026, selling an estimated $522 and leaving 1,156 shares worth $142K. The position accounts for 0.02% of the portfolio, ranked #359.

Truvestments Capital first reported a position in PTGX in Q3 2018 and has held it in 26 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Truvestments Capital held 1,156 shares of Protagonist Therapeutics worth $142K as of Q2 2026.
  • Truvestments Capital sold 5 Protagonist Therapeutics shares in Q2 2026, an estimated $522.
  • Protagonist Therapeutics made up 0.02% of Truvestments Capital's portfolio in Q2 2026, its #359 holding.
  • Truvestments Capital first reported a position in Protagonist Therapeutics in Q3 2018 and has held it in 26 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.